A Prospective Study of FOLFIRI Plus Panitumumab in Extended RAS Wild Type and BRAF Wild Type Metastatic Colorectal Cancer With Acquired Resistance to Prior Cetuximab (or Panitumumab) Plus Irinotecan-Based Therapy and Who Failed at Least One Subsequent Non-anti-EGFR Containing Regimen
Phase of Trial: Phase II
Latest Information Update: 21 Sep 2017
At a glance
- Drugs Panitumumab (Primary) ; Fluorouracil; Folinic acid; Irinotecan
- Indications Colorectal cancer
- Focus Therapeutic Use
- 15 Sep 2017 Status changed from active, no longer recruiting to discontinued.
- 10 Jun 2017 Biomarkers information updated
- 26 Apr 2017 Status changed from recruiting to active, no longer recruiting.